# Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

> **NCT02805244** · PHASE1 · COMPLETED · sponsor: **Akros Pharma Inc.** · enrollment: 6 (actual)

## Conditions studied

- Anemia of Chronic Kidney Disease

## Interventions

- **DRUG:** JTZ-951, 14C-JTZ-951

## Key facts

- **NCT ID:** NCT02805244
- **Lead sponsor:** Akros Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2016-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805244, "Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02805244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*